Floatz logo

JCAR-017 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

Non-Hodgkin Lymphoma

Lyell Immunopharma, Inc.Cell therapyPhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

372 Active assets in the Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclosporin A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Adriamycin
National Cancer Institute (NCI)
Phase 4BBB
Prednisolone
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

JCAR-017 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR is also rated in:

diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BB
Indicative · Phase 2
65 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →